NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/13/2026
Back to search
Official data from USPTO
ENVISIA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
01/13/2026
Trademark type
Word
Nice classes
1, 5
Filing date
02/28/2023
Registration date
01/13/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/13/2026
Last transaction
01/13/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
05/17/2018
First use in commerce
05/17/2018
Drawing code
4
Owner type
03
Owner location
South San Francisco, CA, US
Examiner
LEVINE,HOWARD B
Law office
M60
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Veracyte, Inc.
Representatives
Rosaleen H. Chou KNOBBE, MARTENS, OLSON & BEAR, LLP
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Reagents for scientific or research use; Diagnostic kits and test kits primarily composed of reagents for determination of genomic and transcriptomic information for scientific or research purposes; Testing kits comprised primarily of preparationsreagentstest stripscollection tubesbufferstube holderstransport bags and assays for use in scientific or research in the fields of diagnosticsmedical diagnosticsclinical diagnosticscompanion diagnosticsmedical treatmentmedical researchclinical researchmedical laboratory researchlaboratory medicinegenetic testingnucleic acid sequencinggeneticsgenotypinglife sciencesbiologyoncologycancersthyroid cancerlung cancerbreast cancerprostate cancerbladder cancerkidney cancercolon cancerinterstitial lung diseaseslymphomadiseasesinfectious diseasesrelated diseases; Biological agentsreagentsassaysenzymesnucleotidesbufferschemical preparationsbiological preparations for scientific and research use; Diagnostic reagents and preparationsother than for medical and veterinary use; Kits comprised primarily of biological reagents and comprised secondarily of a protocol in the form of printed instructions for use thereof for scientific and research purposes; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for scientific or research purposes; Reagents and molecule or cell markers for scientific or research purposes
Class 5
Kits for in vitro diagnostic testing for pulmonary diseases and conditions; Reagents for medical use; Molecular diagnostic assays for testing of bodily fluidstissuecellsblooddiseasecancergeneticspathogens; Medical preparations used to diagnose bodily fluidstissuecellsblooddiseasecancergeneticspathogens; Diagnostic agentspreparations and substances for medical purposes; Diagnostic test kits consisting primarily of reagents for use in testing bodily fluidstissuecellsblooddiseasecancergeneticspathogens; Medical diagnostic test kits consisting primarily of reagents for detecting pathogens; Clinical medical diagnostic reagentsmedical diagnostic assays for medical and diagnostic purposes for testing genetic material; Clinicalgenetic and specialized medical diagnostic test kits comprised primarily of bufferscollection tubestube holderstransport bagsshipping containersinstruction sheets for use in scientific and clinical diagnostic equipment used to detect diseasecancergeneticspathogens; Chemicalsassaysreagents and kits consisting primarily of chemicalsassaysreagents for medical testing and diagnostic purposes in the fields of genomicsdiagnosticsmedical diagnosticsclinical diagnosticscompanion diagnosticsmedical treatmentmedical researchclinical researchmedical laboratory researchlaboratory medicinegenetic testingnucleic acid sequencinggeneticsgenotypinglife sciencesbiologyoncologycancersthyroid cancerlung cancerbreast cancerprostate cancerbladder cancerkidney cancercolon cancerinterstitial lung diseaseslymphomadiseasesinfectious diseasesrelated diseases; Medical diagnostic reagentskits comprised of medical diagnostic reagentscollection tubesbufferstube holderstransport bagsinstruction sheetsfor diagnostic testing in the fields of diagnosticsmedical diagnosticsclinical diagnosticscompanion diagnosticsmedical treatmentmedical researchclinical researchmedical laboratory researchlaboratory medicinegenetic testingnucleic acid sequencinggeneticsgenotypinglife sciencesbiologyoncologycancersthyroid cancerlung cancerbreast cancerprostate cancerbladder cancerkidney cancercolon cancerinterstitial lung diseaseslymphomadiseasesinfectious diseasesrelated diseases; Medical diagnostic testing kits comprised primarily of reagents and assays for use in diagnostics and diagnostic testing in the fields of diagnosticsmedical diagnosticsclinical diagnosticscompanion diagnosticsmedical treatmentmedical researchclinical researchmedical laboratory researchlaboratory medicinegenetic testingnucleic acid sequencinggeneticsgenotypinglife sciencesbiologyoncologycancersthyroid cancerlung cancerbreast cancerprostate cancerbladder cancerkidney cancercolon cancerinterstitial lung diseaseslymphomadiseasesinfectious diseasesrelated diseases; Tests designed to isolate and extract cells for genetic analysis comprised of reagents for medical diagnostic use
Publications
History of USPTO decisions and trademark events.
25 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/13/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/25/2025
PUBO
PUBLISHED FOR OPPOSITION
11/25/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/19/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/28/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/27/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/27/2025
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
10/27/2025
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
06/25/2025
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
12/27/2024
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/28/2024
GNSL
LETTER OF SUSPENSION E-MAILED
06/28/2024
CNSL
SUSPENSION LETTER WRITTEN
06/28/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/29/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/29/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/29/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
02/22/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
02/22/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/29/2023
GNRT
NON-FINAL ACTION E-MAILED
11/29/2023
CNRT
NON-FINAL ACTION WRITTEN
11/29/2023
DOCK
ASSIGNED TO EXAMINER
11/29/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/19/2023
NWAP
NEW APPLICATION ENTERED
03/03/2023
Continuous trademark protection
Get notified about every new filing that threatens ENVISIA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.